Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.
1. A compound having the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
X is —COOH or tetrazolyl;
R 1 and R 2 are independently selected from the group consisting of: halo, C 1-4 -alkyl, C 1-4 -fluoroalkyl, C 1-4 alkoxy, C 1-4 -fluoroalkoxy and acetyl.
2. The compound according to claim 1 of Formula Ia
or a pharmaceutically acceptable salt thereof, wherein the variables R 1 and R 2 are as previously defined.
3. The compound according to claim 2 of Formula Ib
or a pharmaceutically acceptable salt thereof, wherein the variables R 1 and R 2 are as previously defined.
4. The compound according to claim 3 of Formula Ic
or a pharmaceutically acceptable salt thereof, wherein the variables R 1 and R 2 are as previously defined.
5. The compound according to claim 1 selected from the following:
or a pharmaceutically acceptable salt of any of the foregoing compounds.
6. The compound of claim 5 , wherein the compound is a diethylamine, sodium, potassium and L-lysine salt thereof.
7. A pharmaceutical composition comprising a compound according to claim 1 in admixture with one or more physiologically acceptable carriers or excipients.
8. A compound having the following formula:
or a pharmaceutically acceptable salt thereof.